CTS embraces a company-wide operational excellence initiative designed to change the culture to enhance operations and the service CTS provides to its healthcare partners. As a result of this initiative, CTS teams significantly improved performance in reporting test results on time and increased efficiency by over 10 percent.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...